Vera Moura - Publications

Nucleolin Overexpression Predicts Patient Prognosis While Providing a Framework for Targeted Therapeutic Intervention in Lung Cancer.

Journal: Cancers

Published: March 11, 2022

Targeted liposomal doxorubicin/ceramides combinations: The importance to assess the nature of drug interaction beyond bulk tumor cells.

Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Published: September 14, 2021

The Enhanced Efficacy of Intracellular Delivery of Doxorubicin/C6-Ceramide Combination Mediated by the F3 Peptide/Nucleolin System Is Supported by the Downregulation of the PI3K/Akt Pathway.

Journal: Cancers

Published: May 21, 2021

Modelling the impact of nucleolin expression level on the activity of F3 peptide-targeted pH-sensitive pegylated liposomes containing doxorubicin.

Journal: Drug delivery and translational research

Published: March 29, 2021

Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy.

Journal: Journal of experimental & clinical cancer research : CR

Published: February 24, 2021

Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies.

Journal: Scientific reports

Published: November 28, 2017

Targeting Cancer Stem Cells and Non-Stem Cancer Cells: The Potential of Lipid- Based Nanoparticles.

Journal: Current pharmaceutical design

Published: October 17, 2017

The cancer stem cell phenotype as a determinant factor of the heterotypic nature of breast tumors.

Journal: Critical reviews in oncology/hematology

Published: November 20, 2016

Inoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine Model.

Journal: PloS one

Published: June 27, 2016

Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.

Journal: Biomaterials

Published: March 17, 2015

Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: May 26, 2014

Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment.

Journal: International journal of pharmaceutics

Published: February 26, 2012